Abstract:4060 Background: Gastric cancer is the 2nd most common cause of cancer deaths worldwide. Currently, endoscopy is the only reliable method for early diagnosis. However, the invasiveness and cost limit its usage as a screening test. MicroRNAs (miRNAs) have been shown to be important in the pathogenesis of cancers. They are exceptionally stable in body fluids, making them potential noninvasive biomarker for cancers. Methods: We screened 600 miRNAs using our MiRXES qPCR technology in the sera of 236 gastric cancer subjects and 236 matched high risk subjects, serving as the discovery set. 191 miRNAs were reliably detected in all the serum samples, out of which 75 informative ones were identified to be significantly (false discovered corrected P value lower than 0.01) altered between gastric cancer and high risk subjects. Multivariate miRNA biomarker panels were then formulated by sequence forward floating search and support vector machine using all the quantitative data obtained for the expression of 191 miRNAs. Results: Multiple iterations of two-fold cross-validation were performed in silico where the panels with 8 or more miRNAs consistently achieved high accuracy [areas under the curve (AUC) ≥ 0.87 in the receiver operating characteristic (ROC) curve]. A 24-miRNA model was optimized based on the discovery set [AUC = 0.92 ( 95% Confidence Interval [CI]: 0.88-0.95)] and validated in two blinded studies with fixed algorithm and threshold definition; Korean case-control cohort (n = 129, 74 cancer cases) and Singaporean Chinese case-control cohort (n = 89, 20 cancer cases). The 24-miR panel showed 90% sensitivity and 81% specificity in the Korean cohort (AUC = 0.91 (95% CI: 0.86-0.96)] and had 90% sensitivity and 75% specificity in the Singaporean Chinese cohort [AUC = 0.89 (95% CI: 0.79-0.99)]. Importantly, the 24-miR panel was able to distinguish stage 1 and 2 gastric cancer in both Korean [AUC = 0.88 (95% CI: 0.81-0.96)] and Singaporean Chinese [AUC = 0.91 (95% CI: 0.80-1.00)] cohorts. Conclusions: We have identified a serum miRNA panel which can confidently differentiate patients with gastric cancer including the early-staged cancers from controls. This may be able to serve as a non-invasive screening test for gastric cancer which warrants study in larger cohorts.

Serum extracellular vesicle-derived miR-21-5p and miR-26a-5p as non-invasive diagnostic potential biomarkers for gastric cancer: A preliminary study

Identification of Serum Circulating MicroRNAs as Novel Diagnostic Biomarkers of Gastric Cancer

Circulating MiR-1290 As a Potential Diagnostic and Disease Monitoring Biomarker of Human Gastrointestinal Tumors

A Serum Microrna Biomarker Panel for Detection of Gastric Cancer.

Serum Microrna Panel Excavated by Machine Learning As a Potential Biomarker for the Detection of Gastric Cancer

Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer

Identification of Serum MicroRNAs As Novel Non-Invasive Biomarkers for Early Detection of Gastric Cancer

Screening of Serum Exosomal miRNAs as Diagnostic Biomarkers for Gastric Cancer Using Small RNA Sequencing

MiRNA-21-5p and MiRNA-125-5p Serve as Biomarkers for Diagnosis and Prognosis of Gastric Cancer

Five Serum-Based Mirnas Were Identified As Potential Diagnostic Biomarkers in Gastric Cardia Adenocarcinoma.

Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer.

Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer

Exosomal miR-590-5p in Serum as a Biomarker for the Diagnosis and Prognosis of Gastric Cancer

A Five-Microrna Signature Identified from Genome-Wide Serum Microrna Expression Profiling Serves As a Fingerprint for Gastric Cancer Diagnosis

Prospective Validation of a Serum Mirna Panel for Early Detection of Gastric Cancer.

Serum microRNA-381: A Potential Marker for Early Diagnosis of Gastric Cancer

MiR-191 and Mir-27A in Plasma Are Promising Novel Biomarkers for Detection of Gastric Cancer

Serum tRF-27-FDXXE6XRK45 as a Promising Biomarker for the Clinical Diagnosis in Gastric Cancer

Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer

Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population

Serum Microrna Signatures and Metabolomics Have High Diagnostic Value in Gastric Cancer